deltatrials
Terminated PHASE2 NCT00089778

Vaccine Treatment of Kidney Cancer

Immunization of Patients With Renal Cancer Using HLA-A2 and HLA-A3-Binding Peptides From Fibroblast Growth Factors 5 (FGF-5)

Sponsor: National Cancer Institute (NCI)

Conditions Kidney Cancer
Interventions 117-126:Fibroblast growth factor 5 (FGF-5) Fibroblast growth factor 5 (FGF-5):172-176/217-220 IL-2
Updated 7 times since 2017 Last updated: Jul 3, 2017 Started: Sep 10, 2004 Primary completion: Aug 5, 2008 Completion: Aug 5, 2008

This PHASE2 trial investigates Kidney Cancer and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Sep 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Aug 2017 — Sep 2017 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States